S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
Copper Exploration Heating Up (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
Copper Exploration Heating Up (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
Copper Exploration Heating Up (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
Copper Exploration Heating Up (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
NASDAQ:INMD

InMode - INMD Stock Forecast, Price & News

$38.18
-0.21 (-0.55%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$37.65
$39.29
50-Day Range
$27.25
$38.71
52-Week Range
$20.60
$75.74
Volume
968,880 shs
Average Volume
1.26 million shs
Market Capitalization
$3.18 billion
P/E Ratio
18.44
Dividend Yield
N/A
Price Target
$46.60

InMode MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
22.1% Upside
$46.60 Price Target
Short Interest
Bearish
7.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
20.10%
From $2.09 to $2.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

637th out of 1,047 stocks

Electromedical Equipment Industry

10th out of 23 stocks

INMD stock logo

About InMode (NASDAQ:INMD) Stock

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Stock News Headlines

Is InMode Stock a Buy Now?
Up 58% in 6 Months, Is InMode Stock Still a Bargain Buy?
Get Into This Growth Stock for 2023 and Beyond
Why InMode Stock Ignited This Week
InMode Ltd. (INMD) Q3 2022 Earnings Call Transcript
Here's Why InMode Stock Soared Today
See More Headlines
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Company Calendar

Last Earnings
10/26/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMD
Fax
N/A
Employees
362
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$46.60
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+22.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$164.97 million
Pretax Margin
44.49%

Debt

Sales & Book Value

Annual Sales
$357.57 million
Cash Flow
$1.97 per share
Book Value
$6.11 per share

Miscellaneous

Free Float
77,481,000
Market Cap
$3.18 billion
Optionable
Not Optionable
Beta
2.20

Social Links


Key Executives

  • Mr. Yair Malca (Age 44)
    Chief Financial Officer
    Comp: $525k
  • Mr. Alon Yaari
    VP of Operations
  • Ms. Nava Tal-Launer
    Chief Information Officer
  • Mr. Shakil Lakhani (Age 39)
    Pres of North America
    Comp: $2.67M
  • Dr. Spero Theodorou M.D. (Age 50)
    Chief Medical Officer
    Comp: $1.84M
  • Mr. Moshe Mizrahy (Age 69)
    Chairman & CEO
  • Dr. Michael Kreindel (Age 54)
    CTO & Director













INMD Stock - Frequently Asked Questions

Should I buy or sell InMode stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INMD shares.
View INMD analyst ratings
or view top-rated stocks.

What is InMode's stock price forecast for 2023?

4 analysts have issued twelve-month price targets for InMode's stock. Their INMD share price forecasts range from $40.00 to $60.00. On average, they predict the company's stock price to reach $46.60 in the next year. This suggests a possible upside of 22.1% from the stock's current price.
View analysts price targets for INMD
or view top-rated stocks among Wall Street analysts.

How have INMD shares performed in 2022?

InMode's stock was trading at $70.58 at the beginning of the year. Since then, INMD shares have decreased by 45.9% and is now trading at $38.18.
View the best growth stocks for 2022 here
.

When is InMode's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our INMD earnings forecast
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) posted its quarterly earnings results on Tuesday, October, 26th. The healthcare company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The healthcare company had revenue of $94.18 million for the quarter, compared to analysts' expectations of $89.38 million. InMode had a trailing twelve-month return on equity of 39.52% and a net margin of 40.93%. InMode's quarterly revenue was up 57.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 earnings per share.

When did InMode's stock split?

InMode shares split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly minted shares were payable to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $2.28-$2.30 for the period, compared to the consensus estimate of $2.22. The company issued revenue guidance of $445.00 million-$450.00 million, compared to the consensus revenue estimate of $440.81 million.

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering (IPO) on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.76%), BlackRock Inc. (2.25%), Meitav Dash Investments Ltd. (1.96%), Two Sigma Advisers LP (1.28%), Point72 Asset Management L.P. (1.23%) and Migdal Insurance & Financial Holdings Ltd. (1.01%).

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $38.18.

How much money does InMode make?

InMode (NASDAQ:INMD) has a market capitalization of $3.18 billion and generates $357.57 million in revenue each year. The healthcare company earns $164.97 million in net income (profit) each year or $2.07 on an earnings per share basis.

How many employees does InMode have?

The company employs 362 workers across the globe.

Does InMode have any subsidiaries?
The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More
How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.

This page (NASDAQ:INMD) was last updated on 12/2/2022 by MarketBeat.com Staff